Navigation Links
Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer
Date:8/23/2010

AMESBURY, Mass., Aug. 23 /PRNewswire/ -- Fluidnet Corporation (www.fluidnet.net), an innovator of advanced intravenous (IV) infusion systems, announced today that its Board of Directors has unanimously appointed Benjamin E. Bulkley as President and Chief Executive Officer, effective immediately. He succeeds the company's Founder, Jeffrey Carlisle, who will serve as Fluidnet's Chief Innovation Officer.

On behalf of the Board of Directors, Chuck Hadley, Chairman, said, "Fluidnet is fortunate to have Ben to lead the company through FDA clearance of its innovative infusion delivery system and drive the growth of the business. His operating successes in the healthcare IT, life sciences, medical device, and transportation industries represent a perfect mix for Fluidnet. His track record growing global businesses and delivering highly reliable, interconnected systems will pay great dividends for the doctors, nurses, and patients that rely on these systems every day."

According to the FDA, more than 56,000 adverse events and over 700 patient deaths over the past five years have been attributed to faulty infusion system design. The Fluidnet system, once cleared, will offer a transformational change in performance. Based on a decade of user-driven innovation, its architecture is the marriage of advanced fluidics, consumer electronics, and state-of-the-art software development methods.

"The opportunity to substantially improve the safety, usability, and reliability of infusion therapy is striking," said Mr. Bulkley. "Providers and regulators are clearly demanding an easier-to-use and more trustworthy solution. I am very excited to be joining such a strong team dedicated to this mission."

Fluidnet closed a Series B financing round of $9.1 million in March of this year to fund ongoing product development, regulatory, and market preparation efforts. The worldwide market for advanced IV delivery systems and accessories is estimated at $3 billion.

Mr. Bulkley was most recently the Chief Operating Officer of Allscripts, a leader in software, services, and connectivity solutions for healthcare providers. He previously led the global commercial operations of Invitrogen, an innovator of biological tools for life science research. He joined Invitrogen after 16 years with the General Electric Company in a variety of leadership roles in the healthcare, energy and transportation fields, ultimately leading the global service business for GE's healthcare IT division.  Mr. Bulkley began his career in systems engineering and program management roles innovating high reliability, low cost solutions in the transportation industry.

Mr. Bulkley holds a Bachelor of Science degree in Electrical Engineering from the University of Connecticut and a Masters degree in Systems Engineering from Gannon University in Pennsylvania.

About Fluidnet

Fluidnet is a developer of advanced IV infusion system solutions that address the growing workflow, connectivity, safety, and regulatory demands across most clinical areas of care. The company currently is finishing the product development, validation, and verification effort, and preparing to submit its 510(k) pre-market notification to the FDA for a multi-use product platform. The system will fully comply with the guidance requirements issued under the agency's new "Infusion Pump Improvement Initiative". For more information see: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/GeneralHospitalDevicesandSupplies/InfusionPumps/ucm205424.htm


'/>"/>
SOURCE Fluidnet Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  A new ... thermoplastics and other highly-engineered materials, is being launched ... tubing has been developed in recent years to ... therapies and surgical applications. More expensive materials such ... produce microextrusion tubing due to their ability to ...
(Date:5/3/2017)... ORANGE COUNTY, Calif. , May 3, 2017 ... vital aspect of any hospital or healthcare facility. ... of examination room is equipped with diagnostic imaging ... and arteries of the heart. In these spaces, ... coronary angiography, catheterization, balloon angioplasty, percutaneous coronary intervention, ...
(Date:5/3/2017)... May 3, 2017  Getinge, a leading global ... quality enhancement and cost efficiency within healthcare and ... of contemporary practice demonstrating that intra-aortic balloon counterpulsation ... critically ill patients. The single-center, retrospective, observational study ... volume MEGA ® 50cc intra-aortic balloon (IAB) ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual ... City. He is known for his distinguished expertise and experience in the diagnosis and ... sub-specialty training in treating renovascular disease and aortic aneurysm . He is known ...
(Date:5/24/2017)... Cincinnati, OH (PRWEB) , ... May 24, 2017 , ... ... discreet and comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal ... is why she offers convenient, clear braces in Cincinnati, OH. Patients no longer need ...
(Date:5/24/2017)... Las Vegas, NV (PRWEB) , ... May 24, ... ... Las Vegas, NV, recently completed Course II of the HP3 (High-Performance Periodontal Practice) ... commits himself to learning the latest advancements in his field by attending numerous ...
(Date:5/24/2017)... ... , ... If you are thinking of a visit to San Francisco , fall is ... perfect time to visit. , Business Architecture Associates is pleased to offer 5 days of ... a 4-½ day package for individuals, and as 4-½ day corporate package for up to ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... label food ingredient solutions for the food and beverage industry offers Citri-Fi®, a ... ingredient statements during the purchasing decision process. As a result, labels need to ...
Breaking Medicine News(10 mins):